A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy
Journal of Clinical Research and Applied Medicine · 2022
DOI: 10.5530/jcram.1.2.14 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Research and Applied Medicine, 2022. Verfasst von Sowmya MS und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
MS, S., Manjunath, M., PL, B., KN, R., & Mukesh, M. (2022). A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy. Journal of Clinical Research and Applied Medicine. https://doi.org/10.5530/jcram.1.2.14
Vancouver
MS S, Manjunath M, PL B, KN R, Mukesh M. A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy. Journal of Clinical Research and Applied Medicine. 2022. doi:10.5530/jcram.1.2.14
BibTeX
@article{MS2022,
author = {MS, Sowmya and Manjunath, Manjunath and PL, Basavanna and KN, Ramya and Mukesh, Mukesh},
title = {A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy},
journal = {Journal of Clinical Research and Applied Medicine},
year = {2022},
doi = {10.5530/jcram.1.2.14}
}
EUVIMED